XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

Table 2 Inclusion and exclusion criteria for XALIA

Inclusion	Exclusion
● Female or male patients who are ≥18 years of age	● Patients with acute symptomatic PE*
● Diagnosis of acute DVT, objectively confirmed	● Other exclusion criteria are dependent on local product information
● Indication for anticoagulation therapy for at least 12 weeks
● Patients willing to participate in the study and available for follow-up

*A parallel symptomatic PE is not an exclusion criterion; however, XALIA will not enrol patients with only PE.
DVT, deep vein thrombosis; PE, pulmonary embolism.

ISSN: 1477-9560